CUSP Wealth
Personalised portfoliosIslamic investingPricing and feesAbout usBlogHelp centre

Healthcare

Companies operating in healthcare, pharmaceuticals, and medical innovation.

0 items
Valuation
Price
TXG
10x Genomics, Inc. Class A Common Stock
TXG
38
$3.64B
-
$28.85
-0.69%
FDMT
4D Molecular Therapeutics, Inc. Common Stock
FDMT
38
$461.60M
-
$8.83
-0.06%
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP
66
$3.62M
-
$1.37
-0.72%
ETNB
89bio, Inc. Common Stock
ETNB
50
$2.20B
-
$14.95
0.10%
ABBV
ABBVIE INC.
ABBV
11
$402.35B
-
$227.65
1.28%
ABVC
ABVC BioPharma, Inc. Common Stock
ABVC
27
$30.94M
-
$1.20
-8.40%
ACIU
AC Immune SA Common Stock
ACIU
11
$294.90M
-
$2.33
3.10%
ACAD
ACADIA Pharmaceuticals Inc. Common Stock
ACAD
61
$3.61B
-
$21.07
-1.50%
ADCT
ADC Therapeutics SA
ADCT
33
$133.55M
-
$1.05
-1.84%
ADMA
ADMA Biologics Inc Common Stock
ADMA
72
$1.90B
-
$8.22
-1.20%
AIM
AIM ImmunoTech Inc.
AIM
44
$5.91M
-
$0.39
-12.91%
ALXO
ALX Oncology Holdings Inc. Common Stock
ALXO
27
$212.61M
-
$1.60
5.26%
AMN
AMN Healthcare Services
AMN
55
$1.19B
-
$30.79
0.03%
ANTX
AN2 Therapeutics, Inc. Common Stock
ANTX
50
$170.72M
-
$4.75
6.74%
ANIP
ANI Pharmaceuticals, Inc.
ANIP
72
$1.86B
-
$81.77
0.15%
SPRY
ARS Pharmaceuticals, Inc. Common Stock
SPRY
33
$969.20M
-
$9.74
1.56%
AARD
Aardvark Therapeutics, Inc. Common Stock
AARD
50
$85.08M
-
$3.93
7.97%
ABCL
AbCellera Biologics Inc. Common Shares
ABCL
44
$1.60B
-
$5.24
-1.85%
ABT
Abbott Laboratories
ABT
38
$153.59B
-
$88.13
-1.70%
ABEO
Abeona Therapeutics Inc. Common Stock
ABEO
61
$315.18M
-
$5.53
-0.18%
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

CUSP Wealth

Have any questions or just want to keep in touch?

Follow us on LinkedIn

Chat on WhatsApp

[email protected]

*T&Cs apply

Fees SchedulePrivacy & Cookies PolicyTerms & ConditionsPromo Campaign T&CsPromo Code T&Cs

Cusp Wealth is a DFSA-regulated company with a Category 4 license to serve retail clients under license number 10863 and reference number F011420. We are authorised to advise on financial products and arrange deals in investments. Any information presented here is of a general nature and does not take into account your personal circumstances or financial objectives. All materials used in these communications are for marketing purposes of the Cusp Wealth Application; none are meant to offer to sell, a solicitation of an offer to buy, or a recommendation of any security or other financial instrument. They are not intended to provide investment, other financial, legal, tax, or other advice. Investments involve market volatility, possible capital loss, liquidity limits, and regulatory changes. Past performance of financial products is not a reliable indicator of future results. The value of investments can go down as well as up, and you may lose all or part of your capital. No content from Cusp Wealth should be understood as guaranteeing returns, offering risk-free investments, or promising wealth outcomes. This material is intended for DFSA-defined Retail and/or Professional Clients. If you are unsure of your classification or eligibility, please contact us at support@сuspwealth.com.

Promo offerings are subject to change. Promo offerings are only for all Cusp Wealth users who have deposited new investment amounts into the Personalised portfolio feature between May 20, 2026 - August 20, 2026. Cusp Wealth has the full discretion to approve or deny the promo offerings to any eligible users. Prom offerings are subject to T&Cs and eligibility criteria. For interested persons, certain products and services are structured according to Islamic principles and approved under our DFSA-issued Islamic Endorsement. For more details, please refer to our full disclosure at https://cuspwealth.com/terms-and-conditions.